OptimizeRx Co. (NASDAQ:OPRX) Receives $10.38 Consensus PT from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $10.38.

OPRX has been the subject of several analyst reports. Stifel Nicolaus raised their price objective on OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a report on Tuesday, May 13th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. B. Riley reiterated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Roth Capital reiterated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th.

OptimizeRx Stock Up 2.9%

Shares of NASDAQ OPRX traded up $0.40 during mid-day trading on Monday, hitting $14.18. The company had a trading volume of 1,039,025 shares, compared to its average volume of 288,067. The company has a market capitalization of $262.26 million, a PE ratio of -10.66 and a beta of 1.28. The firm has a 50-day simple moving average of $9.86 and a two-hundred day simple moving average of $7.15. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a one year low of $3.78 and a one year high of $15.08.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. On average, equities analysts expect that OptimizeRx will post -0.33 EPS for the current year.

Insiders Place Their Bets

In related news, Director James Paul Lang acquired 321,408 shares of the business's stock in a transaction on Friday, March 14th. The stock was purchased at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now directly owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. The trade was a 472.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the fourth quarter worth approximately $25,000. GAMMA Investing LLC acquired a new stake in OptimizeRx during the first quarter worth approximately $33,000. SG Americas Securities LLC acquired a new stake in OptimizeRx during the fourth quarter worth approximately $51,000. Wells Fargo & Company MN lifted its position in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after acquiring an additional 2,797 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in OptimizeRx during the fourth quarter worth approximately $81,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.